for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cidara Therapeutics Inc

CDTX.OQ

Latest Trade

2.36USD

Change

-0.04(-1.67%)

Volume

68,585

Today's Range

2.35

 - 

2.52

52 Week Range

1.24

 - 

3.96

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Cidara Reports Qtrly Earnings Per Share $0.08

Nov 7 (Reuters) - Cidara Therapeutics Inc <CDTX.O>::CIDARA PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 REVENUE $19.1 MILLION.Q3 REVENUE ESTIMATE $6 MILLION -- REFINITIV IBES DATA.QTRLY EARNINGS PER SHARE $0.08.Q3 EARNINGS PER SHARE VIEW $-0.26 -- REFINITIV IBES DATA.

Mundipharma AG Reports 15.2% Passive Stake In Cidara Therapeutics

Sept 13 (Reuters) - Cidara Therapeutics Inc <CDTX.O>::MUNDIPHARMA AG REPORTS 15.2% PASSIVE STAKE IN CIDARA THERAPEUTICS AS OF SEPTEMBER 3, 2019 - SEC FILING.

Cidara Therapeutics Says Rezafungin Achieved Positive Topline Results In Its Phase 2 Strive B Trial

Aug 8 (Reuters) - Cidara Therapeutics Inc <CDTX.O>::CIDARA PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.REZAFUNGIN ACHIEVED POSITIVE TOPLINE RESULTS IN ITS PHASE 2 STRIVE B TRIAL.CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $44.6 MILLION AS OF JUNE 30, 2019.QTRLY LOSS PER SHARE $0.49.Q2 EARNINGS PER SHARE VIEW $-0.57 -- REFINITIV IBES DATA.

Cidara Reports Fourth Quarter And Full Year 2018 Financial Results

Feb 28 (Reuters) - Cidara Therapeutics Inc <CDTX.O>::CIDARA PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.CIDARA THERAPEUTICS INC QTRLY NET LOSS PER SHARE $0.44.CIDARA THERAPEUTICS - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $74.6 MILLION AS OF DEC 31, 2018, VERSUS $75.3 MILLION AS OF DECEMBER 31, 2017.

Cidara Therapeutics says May Sell Shares Of Upto $35 mln

Nov 16 (Reuters) - Cidara Therapeutics Inc <CDTX.O>::MAY OFFER, SELL SHARES OF CO'S COMMON STOCK HAVING AGGREGATE OFFERING PRICE OF UP TO $35 MILLION FROM TIME TO TIME - SEC FILING.

Cidara Therapeutics Qtrly Loss Per Share $0.49

Nov 8 (Reuters) - Cidara Therapeutics Inc <CDTX.O>::CIDARA THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.49.CIDARA THERAPEUTICS INC - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $88.3 MILLION AS OF SEPTEMBER 30, 2018.CIDARA THERAPEUTICS INC - FOCUSED ON INITIATING PHASE 3 RESPECT PROPHYLAXIS TRIAL IN Q1 2019.

Cidara Qtrly Loss Per Share $0.49

Nov 8 (Reuters) - Cidara Therapeutics Inc <CDTX.O>::CIDARA PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.CIDARA THERAPEUTICS INC - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $88.3 MILLION AS OF SEPTEMBER 30, 2018.CIDARA THERAPEUTICS INC QTRLY LOSS PER SHARE $0.49.

Cidara Therapeutics Enters Into Controlled Equity Offering

Nov 8 (Reuters) - Cidara Therapeutics Inc <CDTX.O>::CIDARA THERAPEUTICS INC - ON NOVEMBER 8, 2018, ENTERED INTO A CONTROLLED EQUITY OFFERING(SM)SALES AGREEMENT WITH CANTOR FITZGERALD & CO - SEC FILING.CIDARA THERAPEUTICS - MAY OFFER, SELL, FROM TIME TO TIME SHARES OF CO'S COMMON STOCK HAVING AGGREGATE OFFERING PRICE OF UP TO $35.0 MILLION.

Cidara Therapeutics Files For Mixed Shelf Of Up To $150 Mln

Nov 8 (Reuters) - Cidara Therapeutics Inc <CDTX.O>::CIDARA THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING.

FDA Grants Qidp And Fast Track Designations To Cidara Therapeutics’ Rezafungin Prophylaxis Development Program

Sept 25 (Reuters) - Cidara Therapeutics Inc <CDTX.O>::FDA GRANTS QIDP AND FAST TRACK DESIGNATIONS TO CIDARA THERAPEUTICS’ REZAFUNGIN PROPHYLAXIS DEVELOPMENT PROGRAM.CIDARA THERAPEUTICS INC - REZAFUNGIN DESIGNATED FOR PREVENTION OF INVASIVE FUNGAL INFECTIONS IN ADULTS UNDERGOING BONE MARROW TRANSPLANTATION.CIDARA - PLANS TO COMMENCE PHASE 3 CLINICAL TRIAL OF REZAFUNGIN IN PATIENTS UNDERGOING ALLOGENEIC BONE MARROW TRANSPLANTATION IN Q1 2019.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up